FIELD: medicine.;SUBSTANCE: group of inventions relates to medicine and pharmacy. Disclosed is use of 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 or a salt thereof for the treatment of secondary hyperparathyroidism or symptoms thereof in a human subject, having secondary hyperparathyroidism in addition to renal failure, without inducing hypercalcemia in a human subject, where 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 is formulated in a dose for oral or parenteral administration from 40 ng/day to 600 ng/day to a subject; the corresponding composition of 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 of the same purpose and method of treatment. Technical result is that the invention provides a reduction in parathyroid hormone (PTH) levels in the patient's serum; wherein said effect is long-lasting against the zemplar comparison preparation.;EFFECT: invention provides maintenance of calcium levels in women after menopause within a physiologically normal range.;9 cl, 13 dwg, 4 ex
展开▼
机译：领域：药物;发明领域：一组发明涉及药物和药学。公开了2-亚甲基-19-nor-（20S）-1α，25-二羟基维生素D 3 或其盐在患有继发性继发性甲状旁腺功能亢进或其症状的人类受试者中的用途。除肾功能衰竭以外的甲状旁腺功能亢进症，而不会引起高钙血症的人类受试者，其中以口服或口服的方式配制了2-methyl-19-nor-（20S）-1α，25-dihydroxyvitamin D 3 对受试者进行从40 ng /天至600 ng /天的肠胃外给药;具有相同目的和治疗方法的2-亚甲基-19-nor-（20S）-1α，25-二羟基维生素D 3 的相应组成。技术结果是本发明降低了患者血清中甲状旁腺激素（PTH）的水平。其中所述作用相对于黄历比较制剂是持久的。效果：本发明将绝经后妇女的钙水平维持在生理正常范围内。9 cl，13 dwg，4 ex
展开▼
